Two Sigma Investments LP Decreases Stake in Twist Bioscience Co. (NASDAQ:TWST)

Two Sigma Investments LP lowered its position in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 17.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 347,532 shares of the company's stock after selling 72,056 shares during the quarter. Two Sigma Investments LP owned about 0.58% of Twist Bioscience worth $16,150,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in TWST. Arizona State Retirement System increased its stake in shares of Twist Bioscience by 1.3% in the 4th quarter. Arizona State Retirement System now owns 16,985 shares of the company's stock worth $789,000 after acquiring an additional 219 shares in the last quarter. Van ECK Associates Corp grew its holdings in Twist Bioscience by 56.4% in the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company's stock worth $34,000 after purchasing an additional 267 shares during the period. Hillsdale Investment Management Inc. increased its stake in shares of Twist Bioscience by 0.4% during the fourth quarter. Hillsdale Investment Management Inc. now owns 78,000 shares of the company's stock valued at $3,625,000 after purchasing an additional 300 shares in the last quarter. Deerfield Management Company L.P. Series C lifted its holdings in shares of Twist Bioscience by 1.7% during the fourth quarter. Deerfield Management Company L.P. Series C now owns 23,827 shares of the company's stock valued at $1,107,000 after purchasing an additional 403 shares during the last quarter. Finally, Summit Investment Advisors Inc. lifted its holdings in shares of Twist Bioscience by 7.8% during the fourth quarter. Summit Investment Advisors Inc. now owns 6,098 shares of the company's stock valued at $283,000 after purchasing an additional 443 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on TWST shares. Robert W. Baird lowered their price objective on Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating for the company in a research note on Tuesday, May 6th. JPMorgan Chase & Co. dropped their price target on shares of Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating on the stock in a research note on Tuesday, May 6th. The Goldman Sachs Group cut their price objective on shares of Twist Bioscience from $55.00 to $48.00 and set a "buy" rating on the stock in a research report on Tuesday, May 6th. Barclays decreased their target price on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating for the company in a report on Thursday, April 10th. Finally, Guggenheim reiterated a "buy" rating and issued a $50.00 target price on shares of Twist Bioscience in a research note on Tuesday, May 6th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $50.40.

Insider Buying and Selling

In other Twist Bioscience news, CEO Emily M. Leproust sold 1,726 shares of the company's stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $41.68, for a total value of $71,939.68. Following the completion of the transaction, the chief executive officer now directly owns 660,966 shares in the company, valued at $27,549,062.88. This represents a 0.26% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Patrick John Finn sold 1,877 shares of Twist Bioscience stock in a transaction that occurred on Wednesday, May 21st. The shares were sold at an average price of $29.75, for a total transaction of $55,840.75. Following the sale, the chief operating officer now owns 240,783 shares in the company, valued at approximately $7,163,294.25. The trade was a 0.77% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 26,011 shares of company stock valued at $951,499. 3.01% of the stock is owned by company insiders.

Twist Bioscience Stock Performance

Shares of TWST traded up $1.05 during mid-day trading on Tuesday, hitting $29.31. 524,340 shares of the company traded hands, compared to its average volume of 1,094,796. The stock has a market cap of $1.76 billion, a price-to-earnings ratio of -8.67 and a beta of 2.54. The stock has a 50-day moving average price of $36.44 and a two-hundred day moving average price of $42.69. Twist Bioscience Co. has a 1 year low of $27.12 and a 1 year high of $60.90. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.62 and a current ratio of 4.96.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.10). Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The business had revenue of $92.79 million during the quarter, compared to analysts' expectations of $92.00 million. Equities analysts anticipate that Twist Bioscience Co. will post -2.12 earnings per share for the current year.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.